Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.
Kantoff P, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer E, Vogelzang N. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. Journal Of Clinical Oncology 1999, 17: 2506-13. PMID: 10561316, DOI: 10.1200/jco.1999.17.8.2506.Peer-Reviewed Original ResearchConceptsHormone-refractory prostate cancerTreatment failureDisease progressionPain controlSurvival durationProstate cancerResults of treatmentOverall survivalPalliative optionMore frequent responsesPatientsHydrocortisoneLife parametersNew drugsCancerMitoxantroneProgressionSurvivalDiseasePossible benefitsMenTreatmentFrequent responseFailureDurationHYDROCORTISONE (H) WITH OR WITHOUT MITOXANTRONE (M) IN MEN WITH HORMONE REFRACTORY PROSTATE CANCER (HRPC). THE RESULTS OF CALGB 9182
Kantoff P, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer E, Vogelzang N. HYDROCORTISONE (H) WITH OR WITHOUT MITOXANTRONE (M) IN MEN WITH HORMONE REFRACTORY PROSTATE CANCER (HRPC). THE RESULTS OF CALGB 9182. Journal Of Urology 1999, 161: 176.. DOI: 10.1097/00005392-199904010-00708.Peer-Reviewed Original ResearchHormone-refractory prostate cancerRefractory prostate cancerProstate cancerCancerMitoxantroneHydrocortisone